This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hyperion Therapeutics Announces Larry J. Singer As Vice President, Manufacturing

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that Larry J. Singer has joined the company as vice president, Manufacturing. Mr. Singer is an executive with over 30 years of experience in manufacturing and global supply chain operations.

"With the recent launch of Ravicti ® and acquisition of Buphenyl ®, we are pleased to hire an executive of Larry's caliber and wealth of experience to lead our supply operations as we build our commercial presence and reputation in the marketplace," said Donald J. Santel, chief executive officer of Hyperion.

For the past 8 years, Mr. Singer was president of NexGen Consulting Group, LLC providing technical consulting services to the pharma, biotech, food, and consumer products industries. Prior to NexGen, Mr. Singer was senior director, Strategic Supply Chain & head of Biosimilars Division for Biogen Idec, Inc., a biotechnology company. Earlier in his career, he was senior director, Operations at Elan Pharmaceuticals, Inc., a biotechnology company and also held managerial roles at Gilead Sciences, Inc., Dey Laboratories, Syntex Corporation and Wyeth Laboratories. Mr. Singer holds a J.D. from Suffolk University Law School, an M.B.A from University of Phoenix, and a B.Sc. from St. John's University.

About Hyperion Therapeutics Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases and hepatology. The company's first commercial product, Ravicti® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns and markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more information, please visit .
CONTACT: Sylvia Wheeler, Investor Relations
         (650) 794-7834

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs